DARE logo

DARE
Dare Bioscience Inc

24,951
Mkt Cap
$27.66M
Volume
94,404.00
52W High
$9.19
52W Low
$1.27
PE Ratio
-1.31
DARE Fundamentals
Price
$1.74
Prev Close
$1.90
Open
$1.85
50D MA
$1.65
Beta
0.39
Avg. Volume
100,236.88
EPS (Annual)
-$1.20
P/B
8.88
Rev/Employee
$42,924.71
$4.92
Loading...
Loading...
News
all
press releases
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
More News
News Placeholder
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·25d ago
News Placeholder
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
<
1
2
...
>

Latest DARE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.